Can Roche Holding (SWX:ROP) Still Be Cheap After Fresh Trial Wins?

Roche Holding has delivered a strong multi year share price run, helped by a busy drug pipeline and fresh clinical data. This raises a simple question for you as an investor: Is the current price still aligned with what the business is earning today? Roche Holding has returned 82.3% over the past 3 years, so a lot of optimism about its earnings power is already reflected in the recent share price story. Recent Phase III results in kidney disease and neuroimmunology, plus new collaborations...